BIIB · Biogen Inc
Price
Snapshot
50 fields · last close| Market Cap | $34.37B |
| P/E | 41.19 |
| Float | 147.4M |
| Beta | 0.10 |
| Volatility | 5.0% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 79.6 |
| Price | 233.38 |
| Change | +0.31% |
| Prev Close | 232.65 |
| Open | 235.75 |
| Day Low | 232.36 |
| Day High | 236.87 |
| Avg Vol | 1 |
| Avg $ Vol | $300.2M |
| 52W High | 240.99 |
| 52W Low | 138.00 |
| 52W Pos | 92.6% |
| From High | −3.16% |
| From Low | +69.12% |
| Max DD 1Y | −14.34% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +3.22% |
| SMA 50 | +6.22% |
| SMA 200 | +17.97% |
| RSI (14) | 61.5 |
| Vol 30D | 24.6% |
| Vol 90D | 34.8% |
| 1Y Range | 138–241 |
| Daily bars | 899 |
| Perf Week | +3.07% |
| Perf Month | +6.21% |
| Perf Quarter | +16.35% |
| Perf Half Y | +31.18% |
| Perf Year | +61.94% |
| Perf YTD | +31.25% |
| Prev Day | +0.31% |
| Clavix | B+ |
| Debt / Eq | 0.42 |
| Curr Ratio | 2.68 |
| Int Cover | 3.4× |
| FCF Margin | 20.7% |
| Rev Growth | +2.2% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 3 / 35 |
What BIIB does
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
It offers LEQEMBI for the treatment of Alzheimer’s disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies.
Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4.
The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Clavix risk grade
regraded every trading dayBIIB grades B+, 79.6 of 100. Steadiest on Macro Resilience (73), most exposed on News Sentiment (54, mixed). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 3 of 35 in Biotechnology by Clavix score.
How rough the ride is
| BIIB | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.10 | 0.51 |
| Volatilityannualized | 5.0% | 14.6% |
| Max drawdown, past yearworst peak-to-trough fall | −14.3% | — |
| Typical daily movemedian absolute daily change | 1.24% | — |
| Days beyond ±3%of the last 252 sessions | 29 (12%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| BIIB | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.10 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| BIIB | |
|---|---|
| 1 week | +3.1% |
| 1 month | +6.2% |
| Year to date | +31.2% |
| 1 year | +61.9% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| BIIB | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 27 Aug |
| Average score0 most bearish, 100 most bullish | 69 |
| Bullish · bearisharticles above 60 · below 40 | 27 · 2 |
| Directionarticles whose tone is improving vs worsening | 27 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| BIIB | |
|---|---|
| Revenue growthyear over year | +2.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openJPMorgan raised or reset its price target on Biogen, citing what it views as attractive 2027 pipeline catalysts, with the headline referencing a kidney transplant milestone. The article body is very short and provides no further specifics.
Biogen is set to report third-quarter results on October 28. The article notes that in late July the company raised its full-year 2026 profit-per-share guidance (excluding one-off costs) from $15.25-$16.25 to $15.85-$16.85, and that last quarter its Alzheimer's collaboration revenue grew 16% from a year earlier to $63.7 million.
Estuary, a company backed by Biogen, raised $93 million in a Series A funding round led by RA Capital to develop two gene therapies for ADPKD, an inherited kidney disorder.
Biogen reported that its drug litifilimab showed sustained improvement in skin symptoms and was generally well tolerated over 52 weeks in a mid-stage (Phase 2) study of patients with cutaneous lupus erythematosus (CLE), a lupus-related skin condition, who had not responded to standard antimalarial treatments. The results are supported by the FDA's Breakthrough Therapy Designation, which is granted to drugs showing early promise for serious conditions.
JPMorgan upgraded Biogen (BIIB) from Neutral to Overweight and raised its price target from $210 to $300. Shares rose 3.5% in pre-market trading and finished up 2.5% at $231.37.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals Inc | C+ | $31.02B | 38.39 | 0.37 | Compare |
| RVMD | Revolution Medicines Inc | B- | $38.14B | — | 1.44 | Compare |
| INCY | Incyte Corp | B+ | $22.92B | 14.21 | 0.79 | Compare |
| UTHR | United Therapeutics Corp | B | $22.87B | 17.44 | 0.50 | Compare |
| INSM | Insmed Inc | C | $21.02B | — | 0.83 | Compare |
| NTRA | Natera Inc | B- | $56.71B | — | 1.54 | Compare |
| EXEL | Exelixis Inc | B+ | $15.42B | 17.92 | 0.44 | Compare |
| REGN | Regeneron Pharmaceuticals Inc | B+ | $81.41B | 18.81 | 0.13 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.